3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
6
Glioblastoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Phase IB
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Mesonephric Gynecologic Cancer
1
Melanoma
1
Lung Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Brain Neoplasms
1
Advanced Colorectal Cancer
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
101
Radiotherapy
53
Brachytherapy
41
Paclitaxel
37
Carboplatin
36
Surveys and Questionnaires
28
Blood Specimen Collection
20
pembrolizumab
19
Radiation
17
Magnetic Resonance Spectroscopy
17
Drug Therapy
17
Colposcopy
16
Methods
14
Bevacizumab
14
Early Intervention, Educational
12
toripalimab
11
Topotecan
11
Radiotherapy, Intensity-Modulated
11
Papanicolaou Test
11
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
11
Chemoradiotherapy
11
Biopsy
11
camrelizumab
10
Mass Screening
10
Gemcitabine
10
Patient Navigation
9
Papillomavirus Vaccines
9
Nivolumab
9
Fluorodeoxyglucose F18
9
Educational Status
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uterine Cervical Neoplasms
×
defactinib
×
Clear all
NCT05512208
2025-10-22
DURAFAK
University of Oklahoma
Phase 2
Recruiting
55 enrolled